Boehringer Ingelheim, Inflammasome to advance new therapies for retinal diseases

German pharma giant Boehringer Ingelheim has entered into a co-development and license agreement with US-based Inflammasome Therapeutics to develop new retinal disease therapies and reduce the patient burden for eye diseases.

The company is planning to develop up to three therapies for patients with retinal diseases by integrating its retinal disease pipeline portfolio compounds with Inflammasome’s intravitreal (IVT) drug delivery technologies.

Paul Ashton – CEO of Inflammasome Therapeutics said:  “We look forward to working with their [Boehringer Ingelheim] team to leverage our respective technologies and expertise to develop new therapies for devastating retinal diseases leading to blindness.”

The partnership will leverage Inflammasome’s technology to deliver therapeutics in a biodegradable gel formulation into the eye.

Clive R Wood – senior corporate vice president of Boehringer Ingelheim , Discovery Research said: “Boehringer Ingelheim is looking forward to developing Inflammasome’s novel technology for the delivery of our first-in- class retinal disease compounds working jointly with Inflammasome’s highly experienced scientific team.

“This will enable us to develop a broad range of novel therapy options for the many patients with retinal diseases waiting urgently for better and new therapy options.”

Under the agreement, Inflammasome will receive approximately US$160 million in up-front, research and development support and milestone gated development payments.

Inflammasome is also entitled to tiered royalties, subject to future commercial sales of developed products.

There were reportedly an estimated 82 million patients in 2019  in the seven countries, namely the US, Japan, Germany, the UK, Spain, Italy, France affected by one of the three forms of retinal disease — age related macular degeneration, diabetic retinopathy, and diabetic macular edema,

Boehringer Ingelheim, a family-owned company, generated 2018 net sales of nearly €17.5 billion and reported R&D expenditure of approximately €3.2 billion, 18.1% of net sales.

Related posts

• Boehringer Ingelheim bags Ofev FDA approval for SSc-ILD (0)
• Boehringer Ingelheim to initiate phase 2 trial of BI 456906 in obesity, diabetes (0)
• Boehringer Ingelheim, MD Anderson to advance new cancer treatments (0)
• Boehringer Ingelheim secures Ofev FDA approval recommendation for SSc-ILD (0)
• Boehringer Ingelheim acquires Swiss biotech company AMAL Therapeutics (0)
• Boehringer Ingelheim acquires oncolytic virus company ViraTherapeutics (0)
• Humira biosimilar Cyltezo meets objective in phase 3 plaque psoriasis trial (0)

The post Boehringer Ingelheim, Inflammasome to advance new therapies for retinal diseases appeared first on PharmaNewsDaily.com.